Tempus AI Expands Oncology Data and AI Partnership With Bristol Myers Squibb
Tempus AI signed a multi-year deal under which Bristol Myers Squibb licenses its oncology data through 2031 and gains access to the Lens platform.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView and Reuters, Tempus AI has announced a multi-year agreement with Bristol Myers Squibb (BMS). Under its terms, BMS will license Tempus's multimodal oncology data through 2031. The data will be used to identify biological and clinical insights, find new drug targets and develop therapies across BMS's oncology portfolio.
BMS will also get access to the Lens platform, which Tempus describes as an AI-first, agentic system for oncology drug development. Researchers will be able to train and run models on de-identified data in a dedicated environment built on GPU infrastructure. The deal extends an existing partnership that already covers AI and real-world data used to optimize clinical trial design.
why it matters
The financial terms of the agreement were not disclosed in the published materials, so its effect on either company's revenue cannot be assessed. For markets, it is mainly a signal that large drugmakers are increasingly buying access to data and AI tools, while providers of these solutions widen their client base.
tags
instruments
sources
- Tempus Expands Strategic Collaboration with Bristol Myers Squibb — TradingView, 23 October 2026 at 13:00 UTC
- Tempus Expands Strategic Collaboration With Bristol Myers Squibb — Reuters, 23 October 2026 at 13:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗